Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077872 | 0.98 | KDM4E (0.55) | KDM4ETRPV4KCNH2MAP4K4PIK3CA | |
| Hydrochloric Acid SCHEMBL27930121 | 0.98 | KDM4E (0.55) | KDM4ETRPV4KCNH2MAP4K4PIK3CA | |
| SCHEMBL30845950 | 0.79 | TRPV4 (0.52) | KDM4ETRPV4KCNH2MAP4K4PIK3CA | |
| SCHEMBL18231250 | 0.79 | KCNH2 (0.55) | TRPV4KCNH2MAP4K4PIK3CAMINK1 | |
| SCHEMBL7825110 | 0.79 | KDM4E (0.57) | KDM4ENAPRTLMNAALDH1A1TSHR | |
| SCHEMBL244098 | 0.79 | TRPV4 (0.52) | TRPV4KCNH2MAP4K4PIK3CAMINK1 | |
| SCHEMBL2169084 | 0.79 | TRPV4 (0.52) | KDM4ETRPV4KCNH2MAP4K4PIK3CA | |
| SCHEMBL5077871 | 0.79 | TRPV4 (0.52) | KDM4ETRPV4KCNH2MAP4K4PIK3CA | |
| SCHEMBL29948975 | 0.79 | TRPV4 (0.52) | TRPV4KCNH2MAP4K4PIK3CAMINK1 | |
| SCHEMBL8438731 | 0.78 | KDM4E (0.65) | KDM4ENAPRTLMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| CN-103492028-A | Novel sulfonaminoquinoline hepcidin antagonists | VIFOR INT AG | 2014-01-01 | — | — | CN | disclosed |
| EP-2675526-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | Vifor (International) AG (CH) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012110603-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2471363-A1 | Use of aryl-, heteroaryl- and benzylsulfonamide carboxylic acids, -carboxylic acid esters, -carboxylic acid amides and -carbonitriles and/or its salts for increasing stress tolerance in plants | Bayer CropScience AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-1497374-A1 | FILLER REINFORCED POLYETHER IMIDE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF | GENERAL ELECTRIC COMPANY (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087226-A1 | FILLER REINFORCED POLYETHER IMIDE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF | GENERAL ELECTRIC COMPAMY (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | KDM4E 4215/4885TRPV4 1589/4885KCNH2 4218/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | KDM4E 2383/4885TRPV4 1139/4885KCNH2 1436/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | KDM4E 4215/4885TRPV4 1589/4885KCNH2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.